Loading…
●Research use only — not for human or veterinary use
Also known as LY3298176
A dual GLP-1 / GIP receptor co-agonist peptide studied extensively in incretin and metabolic-signaling research. Supplied as a documented reference standard.
Tirzepatide is a dual GLP-1 receptor / GIP receptor co-agonist studied in incretin and metabolic-signaling research. Engaging two incretin receptors with one molecule is precisely what makes it of interest as a research tool for comparative receptor pharmacology.
It is an acylated co-agonist peptide with a molecular weight of ~4,813.5 g/mol. The lipidation that supports its long half-life is also relevant to its handling and analytical profile.
See incretin & GIP co-agonism and the GLP-1 pathway research overview. Tirzepatide sits between the single agonist semaglutide and the triple agonist retatrutide on the agonism spectrum.
Reconstitution without aggregation is covered in reconstituting GLP-1 class peptides; storage temperature and freeze-thaw effects are discussed in freeze-thaw stability of tirzepatide.
Lots are characterised by HPLC, mass spectrometry and counter-ion analysis, documented per lot (see batch traceability).
Tirzepatide is a research-use-only reference standard, available to qualified researchers by enquiry. Mechanism and analytics only — not clinical use, and not for human or veterinary use.
Store lyophilised at -20 °C; reconstituted material at 2–8 °C within the analytical window.
Stable as a lyophilate; reconstituted purity tracked by HPLC over the storage window.
Research use only — All products and content are intended strictly for in-vitro laboratory research and analytical use. Not for human or veterinary use, not for consumption, and not for any diagnostic or therapeutic purpose.
Available to qualified researchers by enquiry. See the pathway overview for mechanism context.
GLP-1 pathway overview